PBHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. PBHC’s technicals are only mildly constructive, but the fundamental/news flow is decisively negative (Q4 loss driven by a large credit-loss provision and deteriorating loan quality). With no proprietary Intellectia buy signals and earnings catalysts skewing risky, an impatient buyer is better off staying out for now (hold/avoid new entry).
Price/Trend (pre-market ~14.24): Near the pivot (14.113) and just below/around first resistance (R1 14.308), meaning upside is immediately capped unless it cleanly breaks above ~14.31. Momentum: MACD histogram is positive (0.0209) and expanding, suggesting short-term bullish momentum is building. RSI: RSI(6) ~55.5 (neutral), so not oversold—no obvious “discount” entry. Moving averages: Converging MAs indicates a non-trending/transitioning market rather than a strong trend. Key levels: Support S1 ~13.919 then S2 ~13.798; Resistance R1 ~14.308 then R2 ~14.429. Pattern-based odds: Model shows a modest positive bias (70% chance of small gains: ~+1.24% next day, +2.78% next week, +6.23% next month), but this is not reinforced by strong catalysts today.
Intellectia Proprietary Trading Signals
Mildly improving short-term momentum (positive/expanding MACD).
If price clears ~14.31 (R
and holds, it could open room toward ~14.43 (R2).
Earnings event (2026-01-30 after hours) can act as a catalyst if credit-quality commentary surprises positively.
Credit deterioration headline risk: Q4 2025 net loss of ~$7M tied to an ~$11.2M credit loss provision (signals worsening loan quality).
Revenue pressure: reported ~25% YoY revenue decline to ~$11.8M in Q4 (per news summary).
Earnings catalyst risk is skewed negative given recent loss/provision narrative.
Trading sentiment indicators: Hedge funds and insiders show neutral/no meaningful accumulation trends recently.
Latest provided quarter (2025/Q3): Revenue ~$12.06M (+0.09% YoY) essentially flat; profitability collapsed with Net Income ~$0.476M (-113.53% YoY) and EPS ~$0.08 (-113.79% YoY), indicating a sharp deterioration in earnings power. More recent quarter context (Q4 2025 from news): Reported GAAP EPS of $1.11 but also a net loss of ~$7M driven by an ~$11.2M credit-loss provision and weaker loan quality; revenue cited at ~$11.8M (-25% YoY). Overall, growth/profit trends look unfavorable due to credit costs and revenue softness.
No analyst rating or price target change data was provided, so there’s no clear Wall Street consensus trend to lean on. Based on available fundamentals alone, the ‘pro’ case would be mean-reversion/technical bounce potential at small-cap bank valuations, while the ‘con’ case (currently stronger) is credit-quality deterioration and earnings volatility tied to provisioning.
